At the time of writing, Travere Therapeutics Inc [TVTX] stock is trading at $34.53, down -1.79%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TVTX shares have gain 15.99% over the last week, with a monthly amount glided 40.14%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Travere Therapeutics Inc [NASDAQ: TVTX] stock has seen the most recent analyst activity on October 31, 2025, when Citigroup reiterated its Buy rating and also boosted its price target to $48 from $34. On June 11, 2025, Citigroup reiterated its Buy rating and revised its price target to $32 on the stock. Cantor Fitzgerald started tracking the stock assigning an Overweight rating. Wells Fargo upgraded its rating to an Overweight and raised its price target to $27 on October 21, 2024. In a note dated September 09, 2024, Guggenheim upgraded a Buy rating on this stock but restated the target price of $25.
For the past year, the stock price of Travere Therapeutics Inc fluctuated between $12.91 and $35.34. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $34.53 at the most recent close of the market. An investor can expect a potential return of 1.36% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
According to Travere Therapeutics Inc [NASDAQ:TVTX], the company’s sales were 435.83M for trailing twelve months, which represents an 162.11% jump. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -0.21%, Pretax Profit Margin comes in at -0.2%, and Net Profit Margin reading is -0.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -1.79 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of4.48.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.70 points at the first support level, and at 32.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.61, and for the 2nd resistance point, it is at 36.69.
Ratios To Look Out For
It is important to note that Travere Therapeutics Inc [NASDAQ:TVTX] has a current ratio of 2.75. As well, the Quick Ratio is 2.71, while the Cash Ratio is 0.82. Considering the valuation of this stock, the price to sales ratio is 7.09, the price to book ratio is 41.99.
Transactions by insiders
Recent insider trading involved Coughlin Timothy, Director, that happened on Oct 31 ’25 when 18000.0 shares were purchased. Officer, Heerma Peter completed a deal on Oct 31 ’25 to buy 5591.0 shares. Meanwhile, CHIEF EXECUTIVE OFFICER Dube Eric M sold 92872.0 shares on Oct 28 ’25.
